Summary

A primary driver for the insulin delivery devices market in South America is the escalating prevalence of diabetes across the region. Urbanization, sedentary lifestyles, and dietary changes have contributed to a significant increase in the number of individuals diagnosed with diabetes. This growing patient population necessitates effective and efficient insulin delivery solutions, driving the demand for a variety of insulin delivery devices. Governments in South American countries have been actively addressing the challenges posed by diabetes through healthcare reforms and targeted initiatives. National diabetes programs, awareness campaigns, and subsidies for diabetes management contribute to creating an environment that supports the adoption of insulin delivery devices. These initiatives are often aimed at improving patient outcomes, reducing the burden on healthcare systems, and addressing the economic impact of diabetes. Growing awareness among patients about the importance of diabetes management and the availability of advanced insulin delivery technologies contributes to market growth. Patients are becoming more proactive in seeking innovative solutions for diabetes care, including user-friendly insulin pens, smart devices, and continuous glucose monitoring systems. Collaborations between pharmaceutical companies, medical device manufacturers, and healthcare providers contribute to the expansion of the insulin delivery devices market. Partnerships facilitate the development and distribution of innovative devices, ensuring a holistic approach to diabetes management. Economic growth in certain South American countries has led to the expansion of the middle class, influencing healthcare expectations and preferences. As individuals achieve higher economic status, there is a growing demand for advanced healthcare solutions, including technologically sophisticated insulin delivery devices.

According to the research report, “South America Insulin Delivery Devices Market Outlook, 2028” published by Bonafide Research, the market is anticipated to add more than USD 600 Million market size from 2023 to 2028. The integration of digital technologies into insulin delivery devices was a prominent trend. This includes smart insulin pens, connected devices, and mobile applications that enable users to track and manage their insulin intake. The trend towards digital health solutions was driven by the increasing emphasis on real-time data monitoring and connectivity to enhance diabetes management. Wearable insulin delivery devices, such as insulin pumps and patches, were gaining traction. These devices offer convenience, continuous monitoring, and a more discreet approach to insulin administration. The trend reflects a growing demand for solutions that seamlessly integrate into individuals' daily lives, promoting better adherence to treatment regimens. Integration with continuous glucose monitoring (CGM) systems was a notable trend. Insulin delivery devices were increasingly designed to work seamlessly with CGM technology, offering users a more comprehensive view of their glucose levels and allowing for more precise insulin adjustments. This trend reflected a move towards a more integrated approach to diabetes management. The COVID-19 pandemic accelerated the adoption of remote consultations and virtual clinics. Healthcare providers increasingly utilized telemedicine platforms to conduct consultations, monitor patients, and adjust insulin regimens. This trend not only addressed pandemic-related challenges but also contributed to the on-going evolution of healthcare delivery models.

In terms of country the market is segmented into Brazil, Argentina and Colombia. Brazil has a large and diverse population, making it a key market for healthcare products, including insulin delivery devices. Brazil is one of the largest economies in South America. Its economic strength, coupled with a relatively higher level of healthcare spending compared to some neighbouring countries, contributes to the affordability and accessibility of healthcare technologies, including insulin delivery devices. The economic stability allows for greater investment in advanced medical solutions. Brazil has a relatively well-developed healthcare infrastructure, with a network of hospitals, clinics, and healthcare facilities. This infrastructure supports the distribution, prescription, and utilization of insulin delivery devices. Access to healthcare services is a critical factor in driving the adoption of advanced medical technologies. In addition, Argentina, like many countries, is experiencing an increase in the prevalence of diabetes. The growing burden of diabetes in the population contributes to a higher demand for insulin and insulin delivery devices. Argentina, as part of the global trend, has been witnessing an increased adoption of advanced insulin delivery technologies. This includes the integration of smart features into insulin pens, such as dose memory, Bluetooth connectivity, and compatibility with mobile applications for better diabetes management.

According to the report based on product market in bifurcated into insulin pens, insulin pumps, insulin pen needles, insulin syringes and others insulin delivery devices (insulin transdermal patches, insulin inhalers, insulin jet injection). Insulin syringes are often considered a cost-effective option for insulin delivery. In regions where healthcare costs are a significant consideration for patients, the affordability of insulin syringes can contribute to their popularity and growth in the market. Insulin syringes are widely available and accessible across healthcare settings. Their ubiquity makes them a commonly used method for insulin delivery, especially in regions where other types of insulin delivery devices may be less accessible. Some individuals may prefer insulin syringes due to their simplicity and ease of use. Patients who are comfortable with the administration technique of insulin syringes may choose them over other more complex or technologically advanced insulin delivery devices. Unlike certain insulin delivery devices that may require external power or regular maintenance, insulin syringes are simple and do not have such requirements. This characteristic makes them reliable and easy to use, appealing to patients who prefer a low-maintenance option. Patient advocacy groups and awareness campaigns that promote safe and effective insulin delivery methods can influence patient choices. If these initiatives highlight the reliability and accessibility of insulin syringes, it may contribute to their sustained growth in the market.

The market is divided into home care, hospitals and clinics, and other segments based on the end user segment. The end-user sector for hospitals and clinics in the Italian insulin delivery device market is anticipated to expand quickly. The treatment of diabetes is becoming more and more crucial in clinics and hospitals. To enhance the effectiveness of diabetes therapy, they are integrating contemporary technologies, such as insulin delivery systems. Healthcare facilities seek advanced treatment modalities to enhance patient outcomes. In response to this need, insulin delivery devices—in particular, pumps and integrated systems—are offering more sophisticated and accurate insulin administration options in clinical settings. Accurate insulin dosage and control are essential for managing diabetes in hospital inpatient settings. To ensure optimal glycemic control for hospitalised patients, insulin pumps and advanced delivery systems play a crucial role in delivering insulin to them continuously and accurately throughout their stay. Diabetes, pregnancy, heart problems and hypertension, cancer, respiratory conditions, hearing impairments, movement disorders, wound care, and additional indications (HIV, sleep disorders, kidney disorders, and neurovascular illnesses) are all included in the market's indication section. Poorly controlled diabetes can compromise the immune system, increasing the risk of infections in wounds. Insulin delivery devices that aid in maintaining optimal blood glucose levels may contribute to reducing the risk of infections in individuals with diabetes, thereby supporting wound care efforts. Collaborative efforts between endocrinologists, diabetes specialists, and wound care specialists can lead to integrated care models. Insulin delivery devices may be recommended as part of a comprehensive strategy to address both glycemic control and wound management in individuals with diabetes.

Companies Covered in this report:

Novo Nordisk A/S , Sanofi S.A., Eli Lilly and Company, Medtronic plc , Terumo Corporation, Becton, Dickinson and Company, Insulet Corporation, Biocon Limited , B. Braun Melsungen AG.

Considered in this report:

• Geography: South America
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• South America Insulin Delivery Devices market with its value and forecast along with its segments
• Country-wise Insulin Delivery Devices market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country Covered in this report:

• Brazil
• Argentina
• Colombia

By Product

• Insulin Pens
• Insulin Pumps
• Insulin Pen Needles
• Insulin Syringes
• Others Insulin Delivery Devices (Insulin transdermal patches, insulin inhalers, insulin jet injection)

By Indication

• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Respiratory Diseases
• Hearing Disorders
• Cancer
• Movement Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

By End User

• Home Care
• Hospitals & Clinics
• Others

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Tea industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.





***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents